<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115126</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042574</org_study_id>
    <nct_id>NCT02115126</nct_id>
  </id_info>
  <brief_title>Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant</brief_title>
  <official_title>A Randomized Phase II Trial to Evaluate an EBV Derived Dendritic Cell (DC) Vaccine When Administered Alone or Co-administered With the TLR9 Agonist, DUK-CPG-001, in EBV+ Lymphoma in the Setting of Autologous Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Rizzieri, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-blinded, not placebo controlled, randomized, parallel phase 2 pilot study to&#xD;
      evaluate the immunological response and the safety of Epstein Barr Virus (EBV)-derived tumor&#xD;
      antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines alone or&#xD;
      co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the&#xD;
      setting of autologous stem cell transplant with infusion of mature T cells. Patients will be&#xD;
      randomized to receive vaccine alone or vaccine co-administered with the TLR9 ligand,&#xD;
      DUK-CPG-001. Randomization will be stratified by 2 disease types: Hodgkin lymphoma and&#xD;
      non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
      The primary objectives of this study are to:&#xD;
&#xD;
        1. To assess the ability of an Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded&#xD;
           DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001, to&#xD;
           induce EBV derived tumor antigen specific CD8+ T cell response in patients with EBV+&#xD;
           lymphoma in the setting of autologous stem cell transplant&#xD;
&#xD;
        2. To assess the ability of an Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded&#xD;
           DC vaccine administered alone to induce EBV derived tumor antigen specific CD8+ T cell&#xD;
           response in patients with EBV+ lymphoma in the setting of autologous stem cell&#xD;
           transplant&#xD;
&#xD;
        3. To evaluate the safety of using LMP2- loaded DC vaccine alone or co-administered with&#xD;
           the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the setting of&#xD;
           autologous stem cell transplant&#xD;
&#xD;
      The secondary objectives of this study are to:&#xD;
&#xD;
        1. Evaluate duration of the presence of long term memory cells after administration of an&#xD;
           LMP2 loaded DC vaccine alone or co-administered with the TLR9 ligand, DUK-CPG-001.&#xD;
&#xD;
        2. Evaluate duration of multi-functional CD8 T cell responses after administration of an&#xD;
           LMP2 loaded DC vaccine alone or co-administered with the TLR9 ligand, DUK-CPG-001.&#xD;
&#xD;
        3. Evaluate duration of Th1, Th2 and Th17 CD4 T cell responses as well as CD4+CD25+Foxp3+&#xD;
           regulatory T cell (Treg) responses after administration of an LMP2 loaded DC vaccine&#xD;
           alone or co-administered with the TLR9 ligand, DUK-CPG-001.&#xD;
&#xD;
        4. Evaluate the disease free survival (DFS) of patients with EBV+ lymphoma in the setting&#xD;
           of autologous stem cell transplant who receive LMP2-loaded DC vaccines alone or&#xD;
           co-administered with DUK-CPG-001.&#xD;
&#xD;
      Patient population Patients with EBV+ lymphoma who are in a complete remission (CR) after&#xD;
      salvage therapy with plans to proceed to autologous peripheral stem cell transplant .&#xD;
&#xD;
      Immune response will be defined as an increase in number of spots to 25-fold more than at&#xD;
      baseline, or at least 200 spots per 105 CD8+ T cells, by Day 7 post 2nd vaccination (i.e., a&#xD;
      patient with a baseline of 1 spot/105 CD8+ T cells who achieved 25 spots/million would not be&#xD;
      counted as a response).&#xD;
&#xD;
        1. Leukapheresis #1: The first pheresis will be performed after that patient has obtained a&#xD;
           complete remission, but prior to transplant. Complete remission will be determined based&#xD;
           on Cheson Criteria100. No special preparative regimen is required prior to pheresis but&#xD;
           it must occur at least 2 weeks after most recent chemotherapy and most recent&#xD;
           granulocytic growth factor.&#xD;
&#xD;
           Pheresis will last approximately 4 hours to collect a goal of 1 x 108 nucleated&#xD;
           cells/kg. This will follow standard stem cell transplant Standard Operating Procedures&#xD;
           (SOPs). The cells will be transferred to John Sampson's GMP facility (Duke Brain Tumor&#xD;
           Immunotherapy Processing Laboratory) where the sample will be divided into DC cell&#xD;
           product for making vaccine, T cells for re-infusion during transplant, and research&#xD;
           sample that will go to Yiping Yang's lab.&#xD;
&#xD;
           As described below, they will subsequently be defrosted and the T cells will be infused&#xD;
           at the time of the autologous stem cell transplant. This will follow standard stem cell&#xD;
           transplant Standard Operating Procedures (SOPs).Please see appendix 8.6 Cell collection:&#xD;
           removal of PBMCs by leukapheresis.&#xD;
&#xD;
        2. Leukapheresis # 2: This is a standard-of-care pheresis to collect cells for the&#xD;
           autologous stem cell transplant and will be performed as per the usual stem cell&#xD;
           transplant and pheresis SOP.&#xD;
&#xD;
           Leukapheresis will follow institutional norms.&#xD;
&#xD;
        3. Stem Cell Transplant will follow institutional norms. The standard minimum infusion of&#xD;
           CD34+ PBSC cells required for autologous stem cell transplant is 2 x 106 cd34+ cells/kg&#xD;
           (range 2-7). The standard transplant preparative regimens used are BEAM or BCV.&#xD;
&#xD;
        4. T Cell Infusion: T cells will be thawed and infused through an IV after the autologous&#xD;
           stem cell graft infusion has been completed. This will be infused following the stem&#xD;
           cell transplant Standard Operating Procedure (SOP) for re-infusion of thawed transplant&#xD;
           products (SOP ABMT-GEN-017).&#xD;
&#xD;
        5. Post Transplant Vaccine #1: Nine -13 weeks status PBSC transplant, patients will receive&#xD;
           their first post-transplant vaccination. At the time of vaccination, ANC must be &gt; 1.5.&#xD;
           Delays beyond 13 weeks may be allowed after discussion with the PI. Delays beyond the 13&#xD;
           weeks will be decided on by the PI on a case by case basis but will only be allowed if&#xD;
           delay is due to a slow ANC recovery that has been attributed to a medication or if the&#xD;
           delay was for a non-medical reason.&#xD;
&#xD;
        6. Post Transplant Vaccine #2: Four weeks +/- 7 days after post-transplant vaccine #1, a&#xD;
           second Boost vaccination will be administered. At the time of vaccination ANC must be &gt;&#xD;
           1.5.&#xD;
&#xD;
      1. Subjects who are randomized to the CPG arm will receive CPG immediately after vaccine #1&#xD;
      and vaccine #2.&#xD;
&#xD;
      7) Blood samples for evaluation of immune response will be collected throughout the study&#xD;
      procedures. Specifically, blood samples will be obtained within 7 days prior to initial&#xD;
      leukapheresis. Blood will also be collected prior to receiving vaccine # 1 and #2 on the day&#xD;
      on which vaccine is administered or up to 2 days before hand. In addition, blood will be&#xD;
      drawn 7 days after each vaccination and at one, three and six months after the second&#xD;
      vaccination. These blood samples will be used for analyzing T cell responses as detailed in&#xD;
      section 3.7. The day 7 draws must be drawn +/- 2 day. The one, three and six month draws may&#xD;
      occur +/- 1 week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>7 days post 2nd vaccination</time_frame>
    <description>Immune response will be defined as an increase in number of spots to 25-fold more than at baseline, and at least 200 spots per 105 cluster of differentiation 8 (CD8)+ T cells, by Day 7 post 2nd vaccination (i.e., a patient with a baseline of 1 spot/105 CD8+ T cells who achieved 25 spots/million would not be counted as a response).&#xD;
&quot;Spots&quot; are the readout for immune activation measured by the enzyme-linked immunosorbent spot (ELISPOT) assay. Each spot is indicative of an activated T cell that secrete interferon (IFN)-gamma, a cytokine produced by activated T cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with greater than grade 1 toxicity</measure>
    <time_frame>30 days post last dose of vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the presence of long term memory cells</measure>
    <time_frame>7 days post second dose of vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of multi-functional CD8 T cell responses</measure>
    <time_frame>7 days post second dose of vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Th1, Th2 and Th17 cluster of differentiation 4 (CD4) T cell responses as well as CD4+cluster of differentiation 25 (CD25)+Foxp3+ regulatory T cell (Treg) responses</measure>
    <time_frame>7 days post second dose of vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Number of days from PBSC transplant until disease relapse or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>LMP2A-loaded conventional DC vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMP2A-loaded DC vaccine + DUK-CPG-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LMP2A-loaded conventional DC vaccine</intervention_name>
    <description>Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be &gt; 1.5.&#xD;
Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be &gt; 1.5.&#xD;
Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination.</description>
    <arm_group_label>LMP2A-loaded conventional DC vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DUK-CPG-001</intervention_name>
    <description>On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.&#xD;
DUK-CPG-001 will be stored at -20ÂºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.&#xD;
Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination.</description>
    <arm_group_label>LMP2A-loaded DC vaccine + DUK-CPG-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each patient must meet all of the following inclusion criteria:&#xD;
&#xD;
          -  Patient must have a histologically proven diagnosis of any EBV+ Hodgkin or non-Hodgkin&#xD;
             lymphoma&#xD;
&#xD;
          -  EBV positive will be defined as positive if LMP1 or 2 or EBER are positive. As long as&#xD;
             EBV positive on a prior biopsy, EBV testing will not be required at the time of&#xD;
             relapse. However, if EBV testing performed on a more recent biopsy and it is negative,&#xD;
             that patient will be excluded.&#xD;
&#xD;
          -  Patients must have had persistent, relapsed, or refractory disease to at least one&#xD;
             prior regimen with plans to proceed to autologous stem cell transplant&#xD;
&#xD;
          -  Patients must be in a complete remission at time of initial pheresis for vaccine&#xD;
             preparation; complete remission will be determined using Cheson Criteria100&#xD;
&#xD;
          -  There are no limits on the number of prior therapies allowed&#xD;
&#xD;
          -  Able to give voluntary written informed consent&#xD;
&#xD;
          -  Female subject is either post-menopausal or surgically sterilized or willing to use an&#xD;
             acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine&#xD;
             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the&#xD;
             duration of the study therapy and for 3 months after vaccine #2.&#xD;
&#xD;
          -  Male subject agrees to use an acceptable method for contraception for the duration of&#xD;
             the study therapy and for 3 months after vaccine #2.&#xD;
&#xD;
          -  Patients must be 18 years of age or older.&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  An estimated or measured creatinine clearance of less than 30 ml/min.&#xD;
&#xD;
          -  AST, ALT, total bilirubin &gt; 3 times the upper limit of normal&#xD;
&#xD;
          -  Patients on chronic immunosuppressive therapy for any reason (other than chemotherapy&#xD;
             for HL)&#xD;
&#xD;
          -  Chronic systemic steroid therapy at doses greater than 10mg/day of prednisone or its&#xD;
             equivalent.&#xD;
&#xD;
          -  Female subject is pregnant or lactating. Confirmation that the subject is not pregnant&#xD;
             must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG)&#xD;
             pregnancy test result within 48 hours of enrollment. Pregnancy testing is not required&#xD;
             for post-menopausal or surgically sterilized women.&#xD;
&#xD;
          -  Patient has received other investigational drugs for this disease within 14 days of&#xD;
             enrollment&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
          -  Patients who are HIV positive AND have a CD4 count &lt;50&#xD;
&#xD;
          -  Prior solid organ transplant or allogeneic stem cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Beaven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>David Rizzieri, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

